TICKERNERD
Menu
STVNSTVNHealthcare · Medical Instruments & Supplies

STVN Stock Forecast: Stevanato Group SpA Price Predictions for 2026-2027

Last close, 9 Sept 2026
$20
−0.39% on the day

The 12 Wall Street analysts covering Stevanato Group SpA hold a median 12-month price target of $25 — +23.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 8 Sept 2026 — in the upper half.

Market cap
$5.6B
Ticker Nerd rank
64 / 100
Median analyst target
$25
Analysts covering
12
Revenue$302.0M+7.9% y/y
Operating income$51.3M
Net income$23.0M
Free cash flow−$33.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.3%
1M
−0.1%
YTD
+1.0%
1Y
−23.5%
From 52W high
−26.4%
From 52W low
+51.2%
$13
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stevanato Group SpA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
82
Growth
70
Revisions
70
Volatility
68
Quality
65
Issuance
50
Momentum
43
Accruals
43
Size
22

Value (82): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (43): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30Oct 25Jan 26Apr 26Jul 26STVNHigh $32Median $25Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
9 Buy3 Hold0 Sell
Low $20Median $25High $32

The green dot is the last close — the median target sits +23.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 June 2026TD CowenInitiatesBuy$25
2 June 2026Wolfe ResearchAssumesOutperform$21
6 Mar 2026Morgan StanleyMaintainsEqual-Weight—
5 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026KeybancMaintainsOverweight—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Mar 2025UBSMaintainsNeutral—
13 Dec 2024B of A SecuritiesMaintainsBuy—
13 Dec 2024Wolfe ResearchInitiatesOutperform—
3 Dec 2024Morgan StanleyAssumesEqual-Weight$24 → $23
7 Aug 2024CitigroupMaintainsBuy—
15 July 2024Morgan StanleyMaintainsEqual-Weight—
22 Apr 2024Morgan StanleyMaintainsEqual-Weight—
25 Mar 2024Stephens & Co.ReiteratesOverweight—
1 Nov 2023JefferiesDowngradeHold—
1 Nov 2023Morgan StanleyMaintainsEqual-Weight—
26 Sept 2023Stephens & Co.InitiatesOverweight—
19 Sept 2023CJS SecuritiesInitiatesMarket Outperform—
30 Aug 2023KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Stevanato Group SpA returned −23.5% against +18.5% for the S&P 500, dividends included.

STVN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26STVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.7%
Analysts raising
6
Analysts cutting
4
Fundamentals

Stevanato Group SpA (STVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.9×

Cheaper than 21% of US stocks

Price / sales
4.6×

Cheaper than 27% of US stocks

Price / book
3.1×

Cheaper than 33% of US stocks

EV / EBITDA
20.0×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
7.8%

Higher than 46% of US stocks

Earnings growth (YoY)
−22.7%

Higher than 19% of US stocks

Gross margin
28.7%

Higher than 32% of US stocks

Operating margin
17.2%

Higher than 75% of US stocks

Net margin
11.0%

Higher than 72% of US stocks

Returns & dividend
Return on equity
9.1%

Higher than 61% of US stocks

Return on assets
5.4%

Higher than 78% of US stocks

Dividend yield
1.2%

Higher than 29% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Stevanato Group SpA (STVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Stevanato Group SpA has a market value of $5.6B and an enterprise value of $6.9B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 7.8% year on year.

  • Net income over the same four quarters: $134.6M, a 11.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.48.

  • Free cash flow in the twelve months to 30 June 2026: −$30.7M.

  • Shares outstanding: 273.1M.

  • Trailing P/E: 35.9×; forward P/E: 24.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.22%, paying out 11% of earnings.

  • Stevanato Group SpA employs 6,010 people — $204K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

STVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
STVNStevanato Group SpA$5.6B
64
MMSIMerit Medical Systems, Inc.$5.2B
92
TFXTeleflex, Inc.$6.1B
81
BLCOBausch + Lomb Corp.$6.3B
87
MMEDMiniMed Group, Inc.$6.5B
2
NVSTEnvista Holdings Corp.$4.5B
99
ICUIICU Medical, Inc.$4.0B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stevanato Group SpA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STVN news & analysis

Stevanato Group to Participate in Two Upcoming Investor Conferences

Business Wire · 8 Sept 2026neutral

Stevanato Group announced it will participate in two upcoming investor conferences: the Morgan Stanley Annual Global Healthcare Conference in New York on September 15 and the BofA Global Healthcare Conference on September 22. The company stated this in a press release from its Piombino Dese, Italy headquarters.

Why it matters — STVN watchers may follow these appearances as opportunities for the company to present its drug containment, delivery, and diagnostic solutions to the investment community at major healthcare conferences.

Stevanato Group: Alina Validates The Container-To-Device Flywheel

Seeking Alpha · 29 Aug 2026positive

Stevanato Group is transitioning from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, with its Alina injector seeing commercial adoption. High-value solutions now account for 45% of revenue, growing 16% year-over-year, supported by capacity investments in Fishers and Latina and a portfolio shift toward premium offerings.

Why it matters — STVN watchers would care because the validated commercial adoption of Alina and the shift toward higher-margin integrated offerings signal a durable transformation toward premium, higher-margin customer relationships and potential operating leverage.

Stevanato Group Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Stevanato Group reported second-quarter 2026 revenue growth of 8%, driven by demand for higher-value drug containment and delivery products that lifted profitability. The company also updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.

Why it matters — STVN watchers would care because the quarter shows growth and improved profitability from higher-value products, while the revised full-year outlook reflects a structural change from the Balda C. Brewer divestiture.

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research · 5 Aug 2026positive

Zacks Investment Research highlights Stevanato (STVN) as a stock positioned to outperform the market, citing its above-average growth in financials and outlining three reasons to view it as a solid growth stock.

Why it matters — The piece signals that analysts see Stevanato's financial growth as above-average, which is relevant for investors tracking the company's performance outlook.

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Seeking Alpha published the transcript of Stevanato Group's Q2 2026 earnings call. The excerpt provides only the transcript's headline and does not include any details of the company's financial results or management remarks.

Why it matters — The transcript gives STVN watchers access to management's discussion of the company's second-quarter 2026 performance.

FAQ

Frequently asked questions about STVN stock

What is the STVN stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Stevanato Group SpA have a median 12-month price target of $25, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STVN stock a buy right now?

Of the 12 analysts covering Stevanato Group SpA, 9 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stevanato Group SpA 64 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STVN?

As at 8 Sept 2026, Stevanato Group SpA ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (82 of 100).

Will STVN stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +23.5% from the last close, and Ticker Nerd's factor model ranks Stevanato Group SpA 64 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STVN stock forecast for 2030?

No analyst covering Stevanato Group SpA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.

How has STVN stock performed over the past year?

Stevanato Group SpA returned -23.5% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stevanato Group SpA do?

Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries.

What is the latest news on STVN?

The most recent item we track (Business Wire, 8 Sept 2026): "Stevanato Group to Participate in Two Upcoming Investor Conferences". Stevanato Group announced it will participate in two upcoming investor conferences: the Morgan Stanley Annual Global Healthcare Conference in New York on September 15 and the BofA Global Healthcare Conference on September 22. The company stated this in a press release from its Piombino Dese, Italy headquarters.

Company

About Stevanato Group SpA.

Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries. The company focuses on drug containment, drug delivery, and diagnostic solutions, supplying products and services used across development, clinical, and commercial stages of the drug life cycle. Its portfolio includes containment systems such as vials, cartridges, syringes, and ampoules, alongside drug delivery devices, diagnostic consumables, analytical services, and medical devices. Stevanato Group also offers engineering capabilities through visual inspection, assembling, packaging, and glass-forming machinery, supporting manufacturing and packaging operations for biopharma customers. Headquartered in Piombino Dese, Italy, the company serves a global customer base across multiple healthcare and diagnostic markets.

CEO Mr. Franco Stevanato · 6,010 employees · Italy · https://www.stevanatogroup.com